Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 2Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

Specimen Handling 176Magnetic Resonance Spectroscopy 138Biopsy 102pembrolizumab 81Carboplatin 79Cisplatin 71Nivolumab 65Cyclophosphamide 64Paclitaxel 54Radiotherapy 48Gemcitabine 43durvalumab 39Doxorubicin 35Bevacizumab 34Fluorouracil 33venetoclax 32Dexamethasone 31Rituximab 30atezolizumab 29Radiation 29Capecitabine 28Lenalidomide 27Etoposide 27Prednisone 26Oxaliplatin 26Injections 26Pemetrexed 25Docetaxel 25olaparib 23fludarabine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Decitabine × 30 days × Clear all
NCT04188405 2026-05-22

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡